Compounds for prevention and / or treatment of infections caused by SARS-CoV-2

By using N-(2quinolinyl)-valyl-O-methylaspartyl-(2,6-difluorophenoxy)methyl ketone (QVDM-OPh) and its derivatives, the The problem of insufficient activity of existing anti-SARS-CoV-2 compounds has achieved effective inhibition and prevention of SARS-CoV-2, especially in the complications of COVID-19, significantly reducing viral replication.

CN119072326APending Publication Date: 2024-12-03INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202380017328.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-24
Filing Date
2023-01-19
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing anti-SARS-CoV-2 compounds have insufficient antiviral activity in vivo and in vitro, especially in the prevention and treatment of complications of COVID-19, and the lack of effective differential antiviral agents in the prior art. Distinguish the inhibitory activity of HIV and SARS-CoV-2.

Method used

Using N-(2quinolinyl)-valyl-O-methylaspartyl-(2,6-difluorophenoxy)methyl ketone (QVDM-OPh) and its pharmaceutically acceptable salts Or solvates, as pancaspases inhibitors, significantly reduce the activity of SARS-CoV-2 in cells and in vitro by inhibiting viral replication and preventing new infections.

Benefits of technology

QVDM-OPh exhibits inhibitory activity on SARS-CoV-2 in vivo and in vitro, especially in the COVID-19 hamster model, and its anti-SARS-CoV-2 activity is better than QVE-OPh. Its effectiveness in prevention and treatment was demonstrated.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FDA0004945696060000011
    Figure FDA0004945696060000011
  • Figure HDA0004945696080000011
    Figure HDA0004945696080000011
  • Figure HDA0004945696080000021
    Figure HDA0004945696080000021
Patent Text Reader

Abstract

The present invention relates to the field of treatment and / or prevention of viral infections caused by SARS-CoV-2. The present inventors have found that N-(2 (quinolyl)-valyl-O-methyl aspartyl-(2, 6-difluorophenoxy) methyl ketone is capable of inhibiting SARS-CoV-2 replication both in vitro and in vivo, and compared to inhibition obtained with a non-O-methylated form of the compound (quinolyl-valyl-aspartyl-[-2, 6-difluorophenoxy]-methyl ketone), the effect of inhibiting SARS-CoV-2 replication is significantly improved. This suppression is more important. Therefore, the present invention relates to N-(2 (quinolyl)-valyl-O-methyl aspartyl-(2, 6-difluorophenoxy) methyl ketone, or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention and / or treatment of a viral infection caused by SARS-CoV-2. The invention also relates to pharmaceutical compositions and kits comprising such compounds for the same use.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention is in the field of treatment and / or prevention of viral infections, more particularly viral infections caused by SARS-CoV-2.

[0002] In fact, the present invention relates to a specific compound for use in the treatment and / or prevention of infections caused by SARS-CoV-2, as well as pharmaceutical compositions and kits comprising such a compound, which is N-(2-(quinolyl)-valyl-O-methylaspartyl-(2,6-difluorophenoxy)methyl ketone or a pharmaceutically acceptable salt or solvate thereof. Background Art

[0003] Coronaviruses are single-stranded enveloped RNA viruses belonging to the Coronaviridae family.

[0004] Since the early 21st century, several serious infections caused by coronaviruses have emerged and affected humans. In fact, the severe acute respiratory syndrome coronavirus (SARS-CoV) was first identified in November 2002, while another coronavirus causing severe and sometimes fatal respiratory infections in humans was detected in Saudi Arabia in June 2012 and was named Middle East respiratory syndrome coronavirus (MERS-CoV).

[0005] In December 2019, cases of pneumonia caused by a new coronavirus broke out and spread rapidly around the world. The World Health Organization (WHO) first named the corresponding coronavirus 2019-nCOV, then SARS-CoV-2, and the related disease was named Coronavirus Disease 2019 (COVID-19). Due to the rapid spread of the disease around the world, the WHO declared it a pandemic on March 11, 2020.

[0006] At the level of its genome sequence, the first identified SARS-CoV-2 showed approximately 80% nucleotide identity with SARS-CoV and 50% nucleotide identity with MERS-CoV. In addition, SARS-CoV-2 was quickly recognized as less severe than SARS-CoV and MERS-CoV, but more contagious.

[0007] Most people infected with SARS-CoV-2 develop mild to moderate respiratory illness with at least one of the following symptoms: fever, headache, muscle pain, fatigue, dry cough, difficulty breathing, loss of taste, and loss of smell, but recover without specific treatment. However, older adults and those who have COVID-19 and another medical condition or disorder (such as obesity, cardiovascular disease, diabetes, chronic respiratory disease, and cancer) may develop severe illness. In these cases, illness may progress to pneumonia, also called COVID-19-associated pneumonia or COVID-19 pneumonia, and / or multi-organ failure. Complications of COVID-19 may include acute respiratory distress syndrome (ARDS), acute respiratory failure, and liver or heart damage.

[0008] In light of the above, numerous companies and public research organizations are working hard to discover antiviral compounds that can prevent and / or treat infections caused by SARS-CoV-2.

[0009] In the international application WO 2021 / 228846, the inventors have proposed N-(2(quinolyl)-valyl-glutamyl(2,6-difluorophenoxy)methyl ketone as a potential anti-SARS-CoV-2 compound. The latter is also called "QVE-OPh", "Quinolyl-Val-Glu-OPh" or "QVD-OPh negative control". In fact, QVD-OPh, i.e. N-(2(quinolyl)-valyl-aspartyl-(2,6-difluorophenoxy)methyl ketone, is chemically very close to QVE-OPh, since the two compounds differ in the side chain of one amino acid, which is aspartic acid (Asp or D) for QVD-OPh and glutamic acid (Glu or E) for QVE-OPh. In terms of activity, QVD-OPh is a broad caspase inhibitor, while QVE-OPh does not exhibit caspase inhibitory activity and is therefore used as a negative control for QVD-OPh.

[0010] QVD-OPh can also be implemented in a methylated form, more particularly in an O-methylated form. In this form, designated as QVDM-OPh in the present disclosure, the hydrogen atom of the carboxyl group in the aspartic acid side chain is replaced by a methyl group through an esterification reaction. QVD-OPh has been proposed as an antiviral compound in the international application WO 2009 / 092897. More particularly, the experimental data provided in the application show that QVD-OPh inhibits the apoptotic phenotype of cells infected with HIV due to its caspase inhibitory activity, and also inhibits viral replication. Laforge et al. (2018) (J. Clin. Invest. [Journal of Clinical Research], Vol. 128, pp. 1627-1640) have confirmed the potential anti-HIV activity of QVD-OPh, wherein AIDS disease progression was prevented in SIV-infected rhesus monkeys due to QVD-OPh treatment, which makes it possible to control viral replication for a long time. However, no data on other types of viruses are given in international application WO 2009 / 092897 or in Laforge et al. (2018).

[0011] Even though QVE-OPh does not show any caspase inhibitory activity, the inventors have demonstrated in the international application WO2021 / 228846 that this compound is able to inhibit viral replication, more particularly HIV viral replication and SARS-CoV-2 viral replication. In fact, this compound is very effective in controlling in vitro infections caused by SARS-CoV-2 by inhibiting the replication of SARS-CoV-2 in cells without any toxicity and by preventing viral production and new infections. The experimental data on the anti-SRAS-CoV-2 activity of QVE-OPh are only in vitro data. In addition, it should be noted that this application only compares QVE-OPh with QVD-OPh and QVDM-OPh for experiments involving HIV.

[0012] The present inventors aimed to identify additional anti-SARS-CoV-2 compounds with improved properties. Summary of the invention

[0013] The present invention can achieve the purpose set by the inventor.

[0014] In fact, the inventors have shown that QVDM-OPh exhibits inhibitory activity against SARS-CoV-2 both in vivo and in vitro. More specifically, the compound is effective in controlling SARS-CoV-2 infection in vitro by inhibiting viral replication in cells without any toxicity and by preventing in vitro viral production and new infections. In addition, the anti-SRAS-CoV-2 activity of QVDM-OPh has been demonstrated in hamsters with COVID-19, where QVDM-OPh treatment significantly reduced viral replication in their lungs. At the time of filing this application, it was not clear that QVDM-OPh had such activity. Although QVE-OPh is described as an anti-HIV and anti-SARS-CoV-2 compound in international application WO2021 / 228846, this does not mean that QVDM-OPh, which is well known for its anti-HIV activity, undoubtedly has anti-SARS-CoV-2 activity. Indeed, on the one hand, HIV and SARS-CoV-2 belong to two distinct types of viruses, namely retroviruses and coronaviruses, and on the other hand, QVD-OPh and QVDM-OPh are defined as antiviral agents with a defined spectrum (International application WO 2021 / 228846, page 6, lines 8-10).

[0015] Even more unexpectedly, there was no indication that QVDM-OPh would exhibit greater anti-SARS-CoV-2 activity than QVD-OPh, as demonstrated below in Example 1 for prevention of viral production and new infections ( Figure 5 and Fig. 9 ). Regarding the differences between QVD-OPh and QVDM-OPh, international application WO 2009 / 092897 points out that compounds without O-methylation are less hydrophobic, which is beneficial for their use in aqueous media (paragraph

[057] ), and QVD-OPh is not as stable as QVDM-OPh (paragraph

[0068] ). However, there is no mention or suggestion of their differences in antiviral activity in the prior art. In particular, in international application WO 2021 / 228846 (page 30, lines 24-32), it was observed that QVE-OPh, QVD-OPh and QVDM-OPh had the same antiviral effect on the viral replication of HIV.

[0016] In addition, the inventors have shown that QVDM-OPh exhibits stronger anti-SRAS-CoV-2 activity than QVE-OPh in hamsters with COVID-19, as demonstrated by the compared levels of lung viral load and viral replication ( Fig.10 ).

[0017] Therefore, the present invention relates to compounds having formula (I): (I) Or a pharmaceutically acceptable salt or solvate thereof, for use in preventing and / or treating viral infection caused by SARS-CoV-2.

[0018] The chemical name of the compound of formula (I) is N-(2(quinolinyl)-valyl-O-methylaspartyl-(2,6-difluorophenoxy)methyl ketone, i.e., QVDM-OPh (O-methylated form of QVD-OPh). The compound of formula (I) is a pan-caspase inhibitor commercially available from VWR™, a division of Avantor™, under the reference numbers BIOV2787-1 and BIOV2787-5.

[0019] The expression "pharmaceutically acceptable salt" of a compound of formula (I) means a salt that is pharmaceutically acceptable and has substantially similar biological activity compared to the biological activity of the compound of formula (I), i.e., compared to the anti-SARS-CoV-2 activity of the compound of formula (I). Obviously, the pharmaceutically acceptable salt of the compound of formula (I) is non-toxic. Typically, the pharmaceutically acceptable salt implemented in the present invention is any acid addition salt obtained from the compound of formula (I). The acid addition salt may be an inorganic acid addition salt or an organic acid addition salt. As illustrative and non-limiting examples of such acid addition salts, hydrochloride, chloride, hydrobromide, bromide, phosphate, hydrogen phosphate, dihydrogen phosphate, sulfate, hydrogen sulfate, borate, acetate, bitartrate, carbonate, citrate, formates, lactates, nitrates, oxalates, stearates and succinates may be cited. More particularly, the pharmaceutically acceptable salt of the compound of formula (I) implemented in the present invention is the hydrochloride salt. This salt can be obtained by using hydrogen chloride, which is able to complex with at least one nitrogen atom of the compound of formula (I).

[0020] The expression "pharmaceutically acceptable solvate" of a compound of formula (I) refers to a molecular complex comprising a compound of formula (I) and a stoichiometric or substoichiometric amount of one or more pharmaceutically acceptable solvent molecules (e.g., ethanol or water). The term "hydrate" refers to the case where the solvent is water.

[0021] Pharmaceutically acceptable salts or solvates of compounds of formula (I) can be prepared by techniques well known in the art, such as, for example, techniques involving precipitation steps, filtration steps, crystallization steps, evaporation steps, lyophilization steps and / or ion exchange resins.

[0022] The compounds embodied in the present invention or any pharmaceutically acceptable salt or solvate thereof are used to prevent and / or treat viral infection caused by SARS-CoV-2.

[0023] As used herein, the term "treat / treating / treatment" is intended to include alleviating, reducing or eliminating a condition or disease, in particular a viral infection caused by SARS-CoV-2 and / or signs, symptoms and / or complications associated therewith. Signs or symptoms associated with a condition or disease may be biochemical, cellular, histological, functional or physical, subjective or objective. Complications associated with a condition or disease, in particular a viral infection caused by SARS-CoV-2, may be COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), acute respiratory failure, and liver or heart damage.

[0024] As used herein, the terms "prevent / preventing / prevention" are meant to include not only delaying or preventing the onset of a condition or disease (especially viral infection caused by SARS-CoV-2 and / or signs, symptoms and / or complications associated therewith), but also preventing a patient from acquiring a condition or disease (especially viral infection caused by SARS-CoV-2), or reducing the risk of a patient acquiring a condition or disease (especially viral infection caused by SARS-CoV-2).

[0025] As used herein, the term "SARS-CoV-2" is to be understood not only as the first identified SARS-CoV-2, but also as any variants or mutants thereof. The first identified SARS-CoV-2 is the initially discovered strain of the virus, which is also known as 2019-nCoV, HCoV-19, SARS2, COVID-19 virus, coronavirus, pneumonia virus and human coronavirus 2019. The complete genome (29903 bp ss-RNA) of this coronavirus is available from the NCBI ("National Center for Biotechnology Information") website https: / / www.ncbi.nlm.nih.gov / as the reference sequence NC_045512.2.

[0026] The first identified "mutant or variant" of SARS-CoV-2 can be any mutant or variant that has been identified in at least some countries, such as variant alpha (also known as variant B.1.1.7), variant beta (also known as variant B.1.351), variant gamma (also known as variant P.1), variant delta (also known as variant B.1.617.2) and variant Omicron (also known as variant B.1.1.529) and their sublineages (also known as variants BA.1, BA.2, BA.3, BA.4 and BA.5). The first identified "mutant or variant" of SARS-CoV-2 also covers any mutant or variant whose complete genome exhibits at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or even at least 99% identity with the reference sequence NC_045512.2.

[0027] As used herein, the expression "percent identity between two nucleotide sequences" means the percentage of identical nucleotide residues between the two sequences being compared, which percentage is obtained after performing an optimal alignment (optimal alignment) between the two sequences. The skilled person is aware of different techniques capable of obtaining such percentage identity, which techniques involve homology algorithms or computer programs, such as the program BLAST.

[0028] The identity percentages are statistical and the differences between the two sequences are randomly distributed along these sequences. The differences between the two sequences may consist of different types of modifications of the sequences: deletions, substitutions or additions of nucleotide residues.

[0029] The compounds implemented in the present invention or any pharmaceutically acceptable salts or solvates thereof implemented in the present invention can be formulated into pharmaceutical compositions. Therefore, the present invention also relates to a pharmaceutical composition comprising as an active ingredient a compound having formula (I) as previously defined or a pharmaceutically acceptable salt or solvate thereof for use in preventing and / or treating viral infections caused by SARS-CoV-2.

[0030] Typically, the pharmaceutical compositions embodied in the present invention further comprise at least one pharmaceutically acceptable vehicle.

[0031] As used herein, the expression "pharmaceutically acceptable vehicle" means any substance added to the active ingredient implemented in the present invention to facilitate its transport, avoid its significant degradation in the composition and / or increase its half-life. Advantageously, such pharmaceutically acceptable vehicles are sterile and pyrogen-free, and refer to molecular entities and compositions that do not produce adverse, allergic or other adverse reactions when properly applied to animals (particularly mammals, especially humans). The pharmaceutically acceptable carrier is selected according to the type of application of the pharmaceutical composition of the present invention, in particular as a function of its mode of administration. Advantageously, a pharmaceutically acceptable vehicle refers to a non-toxic, solid, semi-solid or liquid carrier, filler, diluent, additive, excipient, buffer, encapsulating material or any type of formulation aid.

[0032] The pharmaceutical compositions embodied in the present invention can be administered by systemic routes; parenteral routes, such as intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intrasternal, intracranial, intramuscular or subcutaneous routes; topical routes; ocular routes; oral routes; and mucosal routes, such as buccal, nasal, intranasal, rectal and vaginal routes.

[0033] As solid pharmaceutical compositions for oral administration implemented in the present invention, tablets, pills, powders, granules or capsules can be used, in which the active ingredient is mixed with one or more conventionally used inert diluents such as, for example, starch, calcium carbonate, sucrose, lactose or gelatin and possibly other substances such as, for example, lubricants (which may be magnesium stearate or talc), colorants or coatings.

[0034] As liquid pharmaceutical compositions for oral or ophthalmic administration implemented in the present invention, pharmaceutically acceptable suspensions, solutions, emulsions, syrups containing conventionally used inert diluents, and possible other substances such as, for example, wetting products, humectants, sweeteners, flavoring agents, preservatives or thickeners can be used.

[0035] The sterile pharmaceutical composition for parenteral administration implemented in the present invention can be a sterile, aqueous or non-aqueous solution, suspension or emulsion. As a solvent or vehicle, water, propylene glycol, polyethylene glycol, vegetable oil, ester for injection (such as ethyl oleate) or other suitable organic solvents can be used. The composition may also contain adjuvants, such as wetting agents, isotonic agents or emulsifiers.

[0036] Pharmaceutical compositions for topical administration practiced in the present invention may be, for example, creams, lotions, mouth sprays, nasal or eye drops, or aerosols.

[0037] In certain embodiments, the pharmaceutical compositions embodied in the present invention further comprise at least one additional therapeutic agent.

[0038] Therefore, the pharmaceutical composition implemented in the present invention comprises or consists of: (i) a compound of formula (I) as defined above or a pharmaceutically acceptable salt or solvate thereof, (ii) at least one pharmaceutically acceptable vehicle and optionally (iii) at least one additional therapeutic agent. In particular, the pharmaceutical composition implemented in the present invention comprises or consists of: (i) a compound of formula (I) as defined above or a pharmaceutically acceptable salt or solvate thereof, (ii) at least one pharmaceutically acceptable vehicle and (iii) at least one additional therapeutic agent.

[0039] Typically, the additional therapeutic agent present in the pharmaceutical composition implemented in the present invention can be a therapeutic agent that has been used in the prevention and / or treatment of viral infections caused by SARS-CoV-2 and a therapeutic agent that has been used in the prevention and / or treatment of symptoms or complications encountered in viral infections caused by SARS-CoV-2. Advantageously, the additional therapeutic agent present in the pharmaceutical composition implemented in the present invention is selected from the group consisting of: antiviral agents, anti-inflammatory agents, analgesics, muscle relaxants, anesthetics, diuretics and antibiotic agents.

[0040] When the pharmaceutical composition embodied in the present invention comprises at least one additional therapeutic agent which is at least one antiviral agent, it is apparent that the at least one additional antiviral agent is different from the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

[0041] A first example of an antiviral agent that can be used in the present invention is QVE-OPh or a pharmaceutically acceptable salt or solvate thereof, in particular as disclosed in international application WO 2021 / 228846. What has been disclosed for the pharmaceutically acceptable salt or solvate of QVDM-OPh applies mutatis mutandis to the pharmaceutically acceptable salt or solvate of QVE-OPh. In other words, at least one additional therapeutic agent of the pharmaceutical composition implemented in the present invention can be N-(2(quinolinyl)-valyl-glutamyl-(2,6-difluorophenoxy)methyl ketone or a pharmaceutically acceptable salt or solvate thereof.

[0042] As other antiviral agents that can be used in the present invention, viral RNA-dependent RNA polymerase modulators such as nucleotide analogs and fusion inhibitors can be cited. The latter prevents the fusion between the SARS-CoV-2 envelope and the cell membrane, and then prevents SARS-CoV-2 from entering the cell. Advantageously, the fusion inhibitor is a serine / protease inhibitor, angiotensin-converting enzyme 2 (ACE2) inhibitor or an antimalarial / parasiticidal drug. Therefore, the fusion inhibitor that can be used in the present invention is selected from the group consisting of: remdesivir, camostat mesylate, nafamostat mesylate, chloroquine phosphate, hydroxychloroquine, cephalothin, selamectin and mefloquine and its salts such as mefloquine hydrochloride.

[0043] As anti-inflammatory agents that can be used in the present invention, monoclonal antibodies can be cited. The latter are preferably directed against inflammatory interleukins and their receptors such as IL-6 and its receptor. Therefore, the monoclonal antibodies that can be used in the present invention are selected from the group consisting of: tocilizumab, sarilumab and siltuximab.

[0044] Alternatively or additionally, the additional therapeutic agent present in the pharmaceutical composition embodied in the present invention is selected from the group consisting of: cisatracurium besylate, dexamethasone sodium phosphate, dexmedetomidine hydrochloride, fentanyl citrate, furosemide, hydromorphone hydrochloride, ketamine hydrochloride, lorazepam, midazolam hydrochloride, morphine sulfate, norepinephrine bitartrate, rocuronium bromide, vancomycin hydrochloride and vecuronium bromide.

[0045] In a specific embodiment, the pharmaceutical composition implemented in the present invention comprises at least two or at least three additional therapeutic agents selected from the same list or different lists as defined above.

[0046] In a more specific embodiment, the pharmaceutical composition implemented in the present invention comprises or consists of: (i) a compound of formula (I) as defined above or a pharmaceutically acceptable salt or solvate thereof, (ii) at least one pharmaceutically acceptable vehicle, (iii1) at least one additional antiviral agent as defined above and (iii2) at least one anti-inflammatory agent as defined above.

[0047] The dosage of the pharmaceutical composition implemented in the present invention must be a pharmaceutically effective amount. "Pharmaceutically effective amount" means an amount sufficient to prevent or treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the level of the effective dose can be selected differently by those skilled in the art according to factors such as, for example, formulation method, patient's condition (including body weight, sex and age), disease extent, drug form, route of administration, administration cycle (if the administration implements single or divided doses), excretion rate and reaction sensitivity. As known to those skilled in the art, the effective amount can vary according to the use of treatment route, excipients and the possibility of use together with other therapeutic agents.

[0048] The present invention also relates to a kit of parts, which comprises or consists of: a) a compound of formula (I) as defined above or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same, and b) at least one additional therapeutic agent, in particular as defined above, or a pharmaceutical composition comprising at least one additional therapeutic agent, For use in the prevention and / or treatment of viral infections caused by SARS-CoV-2.

[0049] What has been disclosed with respect to pharmaceutical compositions comprising a compound having formula (I) or a pharmaceutically acceptable salt or solvate thereof applies mutatis mutandis to pharmaceutical compositions comprising at least one additional therapeutic agent.

[0050] A kit of parts may also be defined as a combination of elements a) and b) as defined above.

[0051] Such a kit of parts is of particular interest in the present invention when the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one additional therapeutic agent cannot be formulated in the same pharmaceutical composition and / or when the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising the same and at least one additional therapeutic agent or a pharmaceutical composition comprising the same are to be administered separately or sequentially.

[0052] Therefore, the kit of parts embodied in the present invention can be used simultaneously, separately or sequentially, in particular for preventing and / or treating viral infections caused by SARS-CoV-2.

[0053] As used herein, simultaneous use means that element a) as defined above and element b) as defined above are administered to the patient simultaneously. The area of ​​administration at the patient level and thus the route of administration may be the same or different.

[0054] As used herein, separate or sequential use means that elements a) and b) as defined above are administered separately or sequentially, provided that the time period during which element a) exerts its pharmacological effect on the patient and the time period during which element b) exerts its pharmacological effect on the patient at least partially overlap.

[0055] As used herein, "patient", "patient in need", "subject" and "subject in need" mean a subject at risk of developing a viral infection caused by SARS-CoV-2 or a subject already infected by SARS-CoV-2. The subject can be a non-human animal or a human. The infection can be confirmed by detecting SARS-CoV-2 proteins or SARS-CoV-2 specific antibodies in a sample derived from the subject, such as saliva, blood or nasopharyngeal samples. Subjects infected with SARS-CoV-2 can be symptomatic, lack typical symptoms or be asymptomatic. Subjects in need can also be subjects who suffer medium- and long-term effects after recovery from the initial illness. These medium- and long-term effects are referred to as "post-COVID-19 conditions" or "long COVID", in particular "neurological long COVID".

[0056] In addition, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined above, a pharmaceutical composition as defined above, and / or a kit of parts as defined above are used to prevent, inhibit and / or reduce viral replication and / or viral protein synthesis in a subject infected with SARS-CoV-2. In this embodiment, the subject may also be a non-human animal or a human. The prevention or inhibition of viral replication and / or viral protein synthesis may be partial or complete.

[0057] As used herein, the expression "viral replication" includes all steps of the viral replication cycle. In particular, the expression includes the main steps of SARS-CoV-2 replication, including viral entry into cells, formation of viral replication and transcription complexes, viral genomic RNA replication, formation of structural proteins by transcription and translation of negative templates, and assembly of viral particles.

[0058] The ability of the compound of formula (I) as defined above, or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition or a kit of parts to prevent, inhibit and / or reduce viral replication and / or viral protein synthesis can be evaluated, for example, in vitro. Example 1 below sets forth techniques for performing such an evaluation, including Western blot analysis and qRT-PCR analysis.

[0059] In addition, the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use as defined above, the pharmaceutical composition for use as defined above and / or the kit of parts for use as defined above are implemented for use in preventing complications of COVID-19 such as COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), acute respiratory failure, and liver or heart damage.

[0060] The present invention relates to a method for preventing and / or treating viral infection caused by SARS-CoV-2 in a patient in need thereof, wherein the method comprises the step of administering to a patient in need thereof a compound of formula (I) as defined above or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition as defined above, or a kit of parts as defined above.

[0061] As already disclosed for the pharmaceutical composition, the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and elements a) and b) of the kit of parts can be administered by systemic routes; parenteral routes, such as intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intrasternal, intracranial, intramuscular or subcutaneous routes; topical routes; ocular routes; oral routes and mucosal routes, such as buccal, nasal, intranasal, rectal and vaginal routes.

[0062] In addition, as already disclosed for the pharmaceutical composition, the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and elements a) and b) of the kit of parts are to be administered in a pharmaceutically effective amount. The definition given above for pharmaceutical composition applies mutatis mutandis to the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and elements a) and b) of the kit of parts.

[0063] In certain embodiments, such preventive and / or therapeutic methods can be implemented to prevent, inhibit and / or reduce viral replication and / or viral protein synthesis in a subject infected with SARS-CoV-2.

[0064] In another specific embodiment, this preventive and / or therapeutic method can be implemented to prevent complications of COVID-19 such as COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), acute respiratory failure, and liver or heart damage, more particularly in patients in need thereof, and more particularly in subjects infected with SARS-CoV-2.

[0065] Other features and advantages of the present invention will become more apparent to those skilled in the art after reading the following examples, which are given by way of illustration only and not limitation, and with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0066] Figure 1 :Toxicity test of QVDM-OPh peptide on Vero E6 / TMPRS22 cells Vero-E6 / TMPRSS2 cells, either uninfected or infected with SARS-CoV-2 at an MOI of 0.05, were incubated daily with different concentrations of QVDM-OPh at 25 μM, 50 μM, and 100 μM and harvested after 72 h. Cells were washed twice with PBS, followed by viability fixative staining for 30 min at 4°C, then washed and fixed with 2% paraformaldehyde (PFA) and analyzed on a Fortessa Flux cytometer. 30 000 events were recorded for each condition in triplicate. FlowJo software was used for analysis, and percent viability was calculated according to the analysis report. Results represent the mean + / - SD of 4 independent experiments with 3 independent points for each condition.

[0067] Figure 2 : Effect of QVDM-OPh peptide on SARS-CoV-2-induced infection and mortality under fully treated conditions. Flow cytometric analysis for intracellular detection of SARS-CoV-2 spike (S) protein expression in infected cells that were untreated or treated with different compounds.

[0068] A) Vero-E6 / TMPRSS2 cells, either uninfected or infected with SARS-CoV-2 at an MOI of 0.05, were incubated with different concentrations of QVDM-OPh (10 μM, 25 μM, 50 μM, 100 μM), Vx765 (25 μM), or remdesivir (10 μM) for 1 h prior to infection. Afterwards, cells were incubated with drug-containing medium until the end of the experiment (full treatment) without removing the virus from the culture. 72 h post-infection, cells were harvested and stained for mortality and infection analysis. The percentage of infection (%) is presented in each analysis graph.

[0069] B) Results represent the percentage of infection (%) detected by spike protein staining in different infected and treated cells compared to infected untreated groups. Results represent the mean + / - SD of 4 independent experiments with 3 independent points for each condition. GraphPad Prism software (GraphPad Software, Inc., USA) was used to apply One-way ANOVA Inspection, then Dunnett afterwards test To assess statistical significance. (****P<0.0001).

[0070] Figure 3: Effect of QVDM-OPh peptide on viral replication and viral protein expression in vitro under full treatment conditions. Western blot analysis for intracellular detection of SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in infected cells that were untreated or treated with different compounds.

[0071] AB) Vero E6 / TMRPSS2 cells were pretreated with the indicated concentrations of QVDM-OPh peptide or remdesivir for 1 hour before infection with virus at MOI = 0.05. Afterwards, the cells were cultured with drug-containing medium until the end of the experiment (complete treatment). Wells with uninfected cells were used as negative controls for infection. 72 hours after infection, cells were lysed by RIPA buffer and Western blot analysis was performed to detect the expression of spike protein (S) (full length and S1 domain) and nucleocapsid protein (N). GAPDH was used as a loading control. The results represent the mean ± SD from 4 independent experiments, 3 independent points per condition.

[0072] Figure 4 : Effect of QVDM-OPh peptide on viral replication in vitro under full treatment conditions. In-cell qRT-PCR analysis of SARS-CoV-2 spike (S), nucleocapsid (N), and NSP6 genes in infected cells untreated or treated with QVDM-OPH.

[0073] ABC) VeroE6 / TMRPSS2 cells were pretreated with QVDM-OPH peptide at a specified concentration for 1 hour before infection with virus at MOI = 0.05. Afterwards, the cells were cultured with drug-containing medium until the end of the experiment (complete treatment). Wells with uninfected cells were used as negative controls for infection. 72 hours after infection, cells were lysed in LBP buffer for RNA purification, and RT-qPCR analysis was performed to detect gene expression of spike protein (S), nucleocapsid protein (N), and NSP6. The relative mRNA amount of each gene was normalized to GAPDH mRNA expression. The ΔΔCt method was used to calculate the fold change. The results represent the mean ± SD from 4 independent experiments, 3 independent points per condition.

[0074] Figure 5 : Antiviral activity of QVDM-OPh peptide against SARS-CoV-2 in vitro under full treatment conditions. Virus yield in the supernatant of infected cells was quantified by qRT-PCR.

[0075] AB) Vero E6 / TMRPSS2 cells were pretreated with the indicated concentrations of QVD-OPh (QVD), QVDM-OPh (QVDM), or remdesivir for 1 h before infection with virus at MOI = 0.05. Wells with uninfected cells served as negative controls for infection. Thereafter, cells were incubated with drug-containing medium until the end of the experiment (full treatment). At 72 h post-infection, supernatants were collected and viral RNA was extracted. Supernatants were analyzed by real-time PCR using probes targeting the SARS-CoV-2 N gene or NSP6 gene. Results represent mean + SEM (n = 3). One-way ANOVA test, Dunnett's post hoc test Explore comparisons of differences between means. ***p<0.001 compared with the untreated group.

[0076] Figure 6 : Effect of QVDM-OPh peptide on SARS-CoV-2-induced infection and mortality under post-entry treatment conditions. Flow cytometric analysis for the detection of SARS-CoV-2 spike (S) protein expression in infected cells that were untreated or treated with different compounds.

[0077] A) Vero E6 / TMPRSS2 were infected with virus at an MOI of 0.05 for 2 hours, and then the virus was removed from the culture medium. The cells were then incubated with different concentrations of QVDM-OPh (10 μM, 25 μM, 50 μM and 100 μM), Vx765 (25 μM) or remdesivir (10 μM) for 72 hours (post-entry). Drugs were added to the culture medium at different concentrations every day until the end of the experiment. 72 hours after infection, cells were collected and stained for mortality and infection rate analysis. The percentage of infection (%) is presented in each analysis figure.

[0078] B) Results represent mean + SEM of percent inhibition (%) of stained spike protein expression compared to untreated controls (n = 3).

[0079] Figure 7 : Effect of QVDM-OPh peptide on viral replication and viral protein expression in vitro under post-entry treatment conditions. Western blot analysis for intracellular detection of SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in infected cells that were untreated or treated with different compounds.

[0080] AB) Vero E6 / TMPRSS2 cells were infected and then Figure 6The cells were treated with the indicated concentrations of QVDM-OPh or remdesivir under the same conditions as described in . Wells with uninfected cells served as negative controls for infection. At 72 h post-infection, cells were lysed by RIPA buffer and subjected to Western blot analysis to detect the expression of spike protein (S) (full length and S1 domain) and nucleocapsid protein (N). GAPDH was used as a loading control. The results represent the mean ± SD from 4 independent experiments with 3 independent points per condition.

[0081] Figure 8 : Effect of QVDM-OPh peptide on viral replication in vitro under post-entry treatment conditions. In-cell qRT-PCR analysis of SARS-CoV-2 spike (S), nucleocapsid (N), and NSP6 genes in infected cells untreated or treated with QVDM-OPh.

[0082] ABC) Vero E6 / TMPRSS2 cells were infected with viruses at an MOI of 0.05 for 2 hours, and then the viruses were removed from the culture medium. The cells were then incubated with different concentrations of QVDM-OPh for 72 hours (after entry). The drug was added to the culture medium at different concentrations every day until the end of the experiment. Wells with uninfected cells were used as negative controls for infection. At 72 hours after infection, the cells were lysed in LBP buffer for RNA purification, and RT-qPCR analysis was performed to detect gene expression of spike protein (S), nucleocapsid protein (N), and NSP6. The relative mRNA amount of each gene was normalized to GAPDH mRNA expression. The fold change was calculated using the ΔΔCt method. The results represent the mean ± SD from 4 independent experiments, with 3 independent points per condition.

[0083] Fig. 9 : Antiviral activity of QVDM-OPh peptide against SARS-CoV-2 in vitro under post-entry treatment conditions. Virus yield in the supernatant of infected cells was quantified by qRT-PCR.

[0084] AB) Vero E6 / TMPRSS2 cells were infected with virus at an MOI of 0.05 for 2 hours, and then the virus was removed from the culture medium. The cells were then incubated with different concentrations of QVD-OPh (QVD), QVDM-OPh (QVDM), or the indicated concentrations of remdesivir (post-entry). Drugs were added to the culture medium at different concentrations every day until the end of the experiment. Wells with uninfected cells served as negative controls for infection. At 72 hours after infection, the supernatant was collected and viral RNA was extracted. The supernatant was analyzed by real-time PCR using probes targeting the SARS-CoV-2 N gene or the NSP6 gene. The results are expressed as mean + SEM (n = 3). Use One-way ANOVA test followed by Dunnett's post hoc test Explore comparisons of differences between means. and ***p<0.001 compared with the untreated group.

[0085] Fig.10 Effects of QVDM-OPh and QVE-OPh against SARS-CoV-2 in the Golden Syrian Hamster Model of COVID-19 Golden Syrian hamsters were randomly divided into groups on D-3, with 10 5 pfu TCID50 inoculated with SARS-CoV-2. All groups received SARS-CoV-2 via the intranasal (IN) route on day 0 (D0). On D0, QVDM-OPh and QVE-OPh peptides or vehicle were administered via the intraperitoneal (IP) route in a total volume of 10 mL / kg and at each inoculation time point. Test articles were inoculated on D0 (t+1h) and day 1 (D1). Day 2 (D2) was the last day of the study.

[0086] A) Mean body weight change curves between vehicle-, QVE-OPH-, and QVDM-OPH-treated animal groups at D0, D1, and D2 post-infection (compared to D0).

[0087] B) Viral RNA expression levels in the lungs of golden Syrian hamsters inoculated with SARS-CoV-2 at 2 dpi (mean + SD), n = 5 for each point. Results are expressed as 2 -ΔCT Mann-Whitney test comparing infected animals to mock (A). *P < 0.05; **P < 0.01.

[0088] C) Percent reduction in viral replication in lungs obtained from Golden Syrian hamsters inoculated with SARS-CoV-2 at 2 dpi and treated with QVE-OPH or QVDM-OPH compared to vehicle.

[0089] Example 1 Materials and methods Cells, viruses and drugs The African green monkey kidney Vero E6 / TMPRSS2 cell line was kindly obtained from Dr. Andreola Marie-Aline, University of Bordeaux, and maintained in Eagle's medium (Dulbecco's modified Eagle'smedium; Gibco, Invitrogen, supplemented with 10% heat-inactivated FBS, 1% PS (penicillin 10,000 U / ml; streptomycin 10,000 µg / ml) at 37°C in a humidified atmosphere with 5% CO2. The strain BetaCoV / France / IDF0372 / 2020 was provided by the National Reference Centre for Respiratory Viruses, hosted by the Institut Pasteur (Paris, France) and directed by Professor Sylvie van der Werf. The human sample from which strain BetaCoV / France / IDF0372 / 2020 was isolated was provided by Dr. X. Lescure and Professor Y. Yazdanpanah, Bichat Hospital, Paris, France. In addition, strain BetaCoV / France / IDF0372 / 2020 was provided through the European Virus Archive goes Global (EVAG) platform, a project funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 653316. Virus stocks were generated on Vero-E6 cells infected at a multiplicity of infection of 1 × 10-4 PFU. Viruses were harvested 3 days after infection, clarified, and then aliquoted and stored at −80°C. Virus stocks were titrated on Vero-E6 cells by classical plaque assay using semisolid overlays (Avicel, RC581-NFDR080I, DuPont). All infection experiments were performed in a biosafety level 3 (BLS-3) laboratory at the CRC (Cordelier Research Center). The pan-caspase inhibitor Q-VD(OME)-OPH (Catalog No. BIOV2787-5), called QVDM-OPH, and QVE-OPH were purchased from Avantor-VWR and Hello Bio.Remdesivir was purchased from COGER (catalog number AG--CR1-3713-M005), and Vx765 (caspase-1 inhibitor) (catalog number BIOV2781-5) was purchased from VWR, a subsidiary of Avantos.

[0090] Evaluation of antiviral activity, toxicity, and infection inhibition To evaluate the toxicity and antiviral efficacy of QVDM-OPh against Vero E6 cells, the percentage of mortality and the percentage of infected cells were measured by flow cytometry. The cells were cultured overnight in 24-well cell culture dishes at a density of 75 × 10 4cells / well. The next day, cells were pretreated with different doses of designated QVDM-OPh, Vx765, or remdesivir at different concentrations for 1 hour or without pretreatment. Then, the virus was added at an MOI of 0.05 to allow infection for 2 hours in 250 μl / well. After that, complete medium was added to the cell culture to a final volume of 500 μl / well. The same concentration of drugs was added to the cell culture every day. 72 hours after infection, cell supernatants were collected and immediately frozen at -80°C for virus extraction and qRT-PCR amplification. Cells were collected and a portion of the cells were used for flow cytometry analysis to measure infection rates using intracellular staining for the spike protein (SARS-CoV-2 spike protein-Alexa 647, catalog number 51-6490-82, eBioscience) and Cytofix / cytoperm fixation and permeabilization kit (catalog number 554714, BD) according to the manufacturer's instructions. Toxicity was analyzed using active 405 / 452 fixative dye (Cat. No. 130-109-814, Miltenyi Biotec, Germany) according to the manufacturer's instructions. Briefly, cells were washed twice with PBS and then stained with active fixative dye for 30 min at 4°C. Then, cells were permeabilized by Cytofix / cytoperm buffer for 20 min, and after washing twice with permawash buffer, anti-Spike-Alexa 647 was added to the cells for 30 min at 4°C. After staining, cells were fixed with 2% paraformaldehyde (FPA) and analyzed on a Fortessa flow cytometer. 30 000 events were recorded for each condition in triplicate. Analysis was performed using FlowJo software. Another portion of cells was lysed in RIPA lysis buffer (Invitrogen, catalog number 10230544) containing protease (Roche) and phosphatase inhibitors (Invitrogen) for further quantification and immunoblotting analysis or in LBP buffer for RNA purification and RT-qPCR analysis. Each condition was performed in triplicate (n = 3) in the same experiment and repeated for 4 independent experiments.

[0091] Time-of-addition experiment Time-addition experiments were performed using QVDM-OPh (10 μM, 25 μM, 50 μM, and 100 μM), Vx765 (25 μM), and remdesivir (5 μM and 10 μM). Vero E6 cells (75 × 10 3Cells / well) were treated with QVDM-OPh, Vx765, and remdesivir at different stages of viral infection. For the "full-time" treatment, Vero E6 cells were pretreated with drugs for 1 hour before viral infection and then incubated with viruses in the presence of drugs for 2 hours until the end of the experiment. For the "post-entry" experiment, viruses were added to the cells to allow infection for 2 hours, and then the virus-containing supernatant was replaced with drug-containing medium until the end of the experiment.

[0092] RNA extraction and quantitative real-time RT-PCR (qRT-PCR) in Vero E6 / TMPRSS2 cells Extraction of viral RNA from the supernatant Two hundred microliters of cell culture supernatant were used for viral RNA extraction using the MiniBEST Viral RNA / DNA Extraction Kit (Takara, catalog number 9766) according to the manufacturer's instructions. RNA was eluted in 30 μL of RNase-free water.

[0093] Intracellular RNA purification After washing with PBS, cells were lysed with LBP and stored at -80°C. ARN purification was performed using the "Nucleospin RNA PLUS" kit (Machery Nagel, Cat. No. 740984.250) according to the manufacturer's recommended procedure. RNA was eluted in 30 μL of RNase-free water.

[0094] Quantitative real-time RT-PCR (qRT-PCR) Total RNA was converted to cDNA using the PrimeScript RT Reagent Kit with gDNA Removal Agent (Takara Bio, catalog number RR047A) following the manufacturer's recommended procedures. Quantitative PCR was performed using TB Green Premix Ex Taq II (Takara Bio, catalog number RR820A). Briefly, each reaction consisted of a total volume of 25 μL containing the following: 1 μL of each primer [0.4 μM / μL], 2 μL of cDNA (5 ng / μL), 12.5 μL of TB Green Premix Ex Taq II, and 8.5 μL of RNase-free water.

[0095] Real-time PCR was performed using a Bio Rad CFX384 real-time system PCR instrument. The thermal cycling conditions used were as follows: initial denaturation: 95°C for 30 seconds, followed by 40 cycles of amplification at 96°C for 5 seconds and 60°C for 30 seconds. Abdel-Sater et al. (2021) (“A Rapid and Low-Cost protocol for the detection of B.1.1.7lineage of SARS-CoV-2 by using SYBR Green-Based RT-qPCR”, medRxiv preprint doi: https: / / doi.org / 10.1101 / 2021.01.27.21250048 Primers for SARS-CoV-2 nucleocapsid (N), nonstructural protein 6 (NSP6), and spike (S) genes designed and described by ) were purchased from Eurofins. For relative quantification of extracellular viral mRNA, SARS-CoV-2 cDNA (Ct approximately 20 for N and NSP6 genes) was used as a positive control. The calculated Ct values ​​were converted to fold reduction of treated samples compared to the positive control using the ΔCt method (fold change of viral RNA = 2^ΔCt).

[0096] For intracellular mRNA, the threshold cycle (Ct) value for each gene was obtained using the instrument software and the automatic Ct function. The relative mRNA amount of each gene was normalized to GAPDH mRNA expression. The fold change was calculated using the ΔΔCt method. The specific SARS-CoV-2 (N, NSP6, and S) and human (GAPDH) primer sequences used in the experiment are as follows: N-qF: CGTTTGGTGGACCCTCAGAT (SEQ ID NO: 1 in the sequence listing); N-qR: CCCCACTGCGTTCTCCATT (SEQ ID NO: 2 in the sequence listing); NSP6-qF: GGTTGATACTAGTTTGTCTGGTTTT (SEQ ID NO: 3 in the sequence listing); NSP6-qR: AACGAGTGTCAAGATTCATAAG (SEQ ID NO: 4 in the sequence listing); S-qF: GGTTCCATGCTATACATGTCTC (SEQ ID NO: 5 in the sequence listing); S-qR: GGTCTTCGAATCTAAAGTAGTACCA (SEQ ID NO: 6 in the sequence listing); GAPDH-qF: AAGGTCGGAGTCAACGGATTT (SEQ ID NO: 7 in the sequence listing); GAPDH-qR: TGAAGGGGTCATTGATGGCA (SEQ ID NO: 8 in the sequence listing).

[0097] Western blot analysis For Western blot analysis, 40 μg of protein from each spot was resolved on a 4%-12% Bis-Tris-SDS-NUPAGE gel (Invitrogen) and then transferred to a nitrocellulose membrane (Amersham Bioscience). After blocking with 5% BSA in TBS buffer containing 0.05% Tween 20, the membrane was then probed with mouse anti-Spike protein (S1-NTD) (E7M5X) (Ozyme, catalog number 42172S), rabbit anti-nucleocapsid (Fisher Scientific, catalog number MA536086). Equal protein loading was assessed by probing the membrane with rabbit anti-GAPDH (Protein Tech, catalog number 60004-1-AP). The membrane was treated with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit secondary antibodies (Amersham Bioscience). Immunoreactive proteins were detected and quantified by enhanced chemiluminescence (Pierces, USA) using a CCD camera (GBOX, SYNGENE Pxi-4, Ozyme).

[0098] result Treatment with different concentrations of QVDM-OPh peptide showed no toxic effects on Vero E6 / TMPRSS2 cells, regardless of whether these cells were infected with virus at an MOI of 0.05 at 72 hpi ( Figure 1 ).

[0099] The antiviral and mortality effects of different concentrations of QVDM-OPh were evaluated by flow cytometric analysis using intracellular staining against the SARS-CoV-2 spike protein and viability dyes to measure mortality. Remdesivir was used as a positive control and Vx765 as a negative control during the study. The effect of QVDM-OPh on SARS-CoV-2 replication was also evaluated by Western blot analysis of viral protein expression for both the spike and nucleocapsid proteins. Results obtained by flow cytometry and Western blot showed that QVDM-OPh significantly inhibited viral replication at doses of 10 µM (inhibition of approximately 50%) and 25 µM (inhibition of approximately 70%). Complete inhibition was achieved at a concentration of 50 µM (inhibition of approximately 99%). This effect was observed at daily doses within 72 hours after infection and in the presence of virus persisting in the culture (full treatment conditions). This reduction is comparable to that obtained with remdesivir ( Figure 2 and Figure 3 ).

[0100] The inventors then explored the mRNA expression of SARS-CoV-2 viral genes, and more specifically the gene expression of spike (S), nucleocapsid (N), and nonstructural protein 6 or accessory protein ORF6 (NSP6) in infected cells treated or untreated with QVDM-OPh. In fact, QVDM-OPh treatment was able to significantly reduce the relative expression of structural proteins, spike, nucleocapsid, and NSP6 genes in cells ( Figure 4 ).

[0101] Finally, the inventor verified whether QVDM-OPh inhibits the secretion / production of the virus from the cells into the culture medium. To this end, she analyzed the supernatants of infected cells treated with different inhibitors or untreated under full treatment conditions for nucleocapsid (N) and NSP6 gene expression after virus extraction and qRT-PCR. SARS-CoV-2 was significantly reduced in the supernatants of Vero E6 / TMPRSS2 infected cells treated with QVDM-OPh as well as in the supernatants of remdesivir treated cells ( Figure 5 ).

[0102] All of these results were reproduced under post-entry treatment conditions, where cells were infected for 2 h and then the virus was completely removed from the medium replaced with fresh medium. All drugs were added at different concentrations 2 h after infection and daily for 72 h. Experiments performed under post-entry conditions showed the same effects as described for all experiments under full treatment conditions ( Figure 6 , Figure 7 , Figure 8 and Fig. 9 ).

[0103] The inventors' findings demonstrate that the QVDM-OPh peptide is highly effective in controlling SARS-CoV-2 infection in vitro by inhibiting viral replication in cells and preventing viral production and new infections without any toxicity even at concentrations of 25 µM and 50 µM.

[0104] In addition, when QVDM-OPh and QVD-OPh were compared at the same concentration ( Figure 5 and Fig. 9 ), QVDM-OPh was able to inhibit virus secretion / production from cells into the culture medium more effectively than QVD-OPh implemented at the same concentration.

[0105] Example 2 Materials and methods COVID-19 Golden Syrian Hamster Model 1. Ethical Statement Animal housing and experimental procedures were performed in accordance with French and European regulations and the National Research Council's Guide for the Care and Use of Laboratory Animals. The animal facility was approved by the French authorities (protocol N° B 91 962 106). All animal procedures used in this study (including surgery, anesthesia, and euthanasia, where applicable) were submitted to the Experimental Animal Care and Use Committee (Oncomet) of Oncodesign, which was approved by the French authorities (CNREEA protocol N° 91).

[0106] The animal BSL3 facility was approved by the French authorities (protocol N° D92-032-02). All animal procedures used in this study (including surgery, anesthesia, and euthanasia, where applicable) were submitted to the Experimental Animal Care and Use Committee of CEA, which was approved by the French authorities (CETEA DSV – n° 44).

[0107] 2. Housing conditions Animals were maintained in a healthy state free of specific pathogens according to FELASA guidelines. Animals were individually identified. Animals were maintained in housing rooms under controlled environmental conditions, i.e. temperature: 21°C ± 2°C, humidity: 55% ± 10%, photoperiod (12 h light / 12 h dark), H14 filtered air, minimum 12 air exchanges per hour, without recirculation.

[0108] Each cage was labeled with a specific code. The animal enclosures provided sterile and adequate space with bedding, food and water, environmental and social enrichment (group housing) as follows: A3 facilities: IsoRat900N biocontainment system (Techniplast, France), poplar bedding (Select fine, safety grade, France), A04 SP-10 diet (safe grade, France), tap water, and environmental enrichment with burrows and wooden sticks.

[0109] 3. SARS-CoV-2 - SARS-CoV-2 strain “Slovakia / SK-BMC5 / 2020”, originally provided by the European Virus Archive Global (EVAg) (GISAID EPI_ISL_417879, https: / / www.european-virus-archive.com / virus / sars-cov-2-strainslovakiask-bmc52020), prepared and titrated by Oncodesign on Vero E6 / TMPRSS2 cells for infection of hamsters. This strain belongs to the GH clade.

[0110] - Inoculated with 50 × 10 6 Virus production was performed in T175 flasks of Vero E6 / TMPRSS2 cells in a final volume of 40 mL. Cell counts and viability were assessed by 0.25% trypan blue exclusion assay using a ViCell device. Cytopathic effects were confirmed under microscopy after a 48-hour infection time range (with SARS-CoV-2 virus at an MOI of 0.001-0.005). Culture supernatants were harvested, centrifuged (5000 g for 5 minutes) and aliquoted (1 mL aliquots).

[0111] - TCID50 titers of viral stocks were determined on Vero E6 / TMPRSS2 cells. Approximately 2 hours before the assay, cells were plated at 2 × 10 cells / well in a 96-well plate. 4 Cells were plated at a density of 1:100 in a volume of 200 μL of complete growth medium (DMEM 10% FCS). Cells were infected with serial dilutions of the virus stock (8 replicates; first dilution 1:100; 5-fold serial dilutions) at 37°C for 1 h. Fresh medium was added for 72 h, and then the MTS / PMS assay was performed according to the supplier's protocol (Promega, Cat. No. G5430). Plates were read and data were recorded using an ELISA plate reader. Infectivity was expressed as TCID50 / mL / 72 h based on the Spearman-Karber formula.

[0112] Experimental design and treatment 1. Animals Twelve healthy golden Syrian hamsters (female) were obtained from Janvier Laboratories, 6 to 8 weeks old when received.

[0113] 2. Random Grouping The animals were weighed and then divided into 2 even groups of 5. The animals were marked on the tail.

[0114] 3. Processing Treatments were administered via the intraperitoneal (IP) route in a total volume of 10 mL / kg and at each inoculation time point. Test articles were inoculated on day 0 (t + 1 h) and day 1. Treatments with test articles were performed according to the following specified schedule: • Group A animals (vehicle) were inoculated using the intraperitoneal (IP) route (10 mL / kg volume) with 0.9% NaCl supplemented with 2.5% DMSO; • Group B animals (Q-VDM-OPH) received two doses of test compound (10 mL / kg volume, 10 mg / kg dose) by IP route on day 0 (t + 1h) and day 1; • Animals in group C (Q-VE-OPH) received two doses of test compound (10 mL / kg volume, 10 mg / kg dose) via IP route on day 0 (t + 1h) and day 1.

[0115] 4. SARS-CoV-2 challenge The route of administration of SARS-CoV-2 was selected by Oncodesign. The virus was administered intranasally (IN) to isoflurane-anesthetized animals in a total volume of 70 μL (35 μL per nostril). Each animal was administered 10 5 pfu TCID50. All groups received SARS-CoV-2 by IN route on day 0.

[0116] 5. Terminate the animals on day 2 post infection (2 dpi) Animals (n = 12) were terminated on day 2 post infection (2 dpi). Animals were deeply anesthetized with a mixture of Zotal (30 mg / kg – 0.6 mL / kg) and Xylazine (10 mg / kg – 0.5 mL / kg) injected via IP route. Before lung collection, gentle cervical dislocation was performed followed by thoracotomy.

[0117] The right upper lobe was placed in RNAlater overnight at 4°C and then stored at −80°C until RNA extraction for quantification of viral load by qRT-PCR. The middle lobe, posterior vena cava, and right lower lobe were snap-frozen in liquid nitrogen (one lobe per tube) and then stored at −80°C until further use.

[0118] In vitro analysis 1- Determination of viral load in lungs by genomic RT-qPCR Lung viral load was quantified by RT-qPCR using the viral ORF1ab gene. Viral RNA extraction was performed using the Macherey Nagel Viral RNA Kit (Cat. No. 740452.4). RNA was frozen at -80°C until qRT-PCR. The complete qRT-PCR was run using the SuperScript™ III One-Step qRT-PCR System Kit (Commercial Kit #1732-020, Life Technologies) with primers and qRT-PCR conditions for the ORF1ab gene. Amplification was performed using the Bio-Rad CFX384™ and connected software. The primers and probes used to perform this quantification were: ORF1ab_Fw: CCGCAAGGTTCTTCTTCGTAAG (SEQ ID NO: 9 in the sequence listing); ORF1ab_Rv: TGCTATGTTTAGTGTTCCAGTTTTC (SEQ ID NO: 10 in the sequence listing); ORF1ab_probe: Hex-AAGGATCAGTGCCAAGCTCGTCGCC-BHQ-1 (SEQ ID NO: 11 in the sequence list), wherein Hex at the 5'-terminal position represents hexachlorofluorescein, and BHQ-1 at the 3'-terminal position represents black hole quencher-1.

[0119] 2- Animal monitoring Clinical monitoring Animals were monitored daily for vitality, behavior, and body weight following SARS-CoV-2 infection. Model-specific clinical follow-up was recorded daily following SARS-CoV-2 infection using the parameters listed below: - Weight loss - Piloerection (none - mild - significant) - Behavior (normal - less mobile - loose or withdrawn) - Posture (normal - abnormal - hunchback) - Cough (present or absent) - Sneezing (presence or absence) Humane End The humane endpoint is determined as follows: - 20% weight loss (compared to the first day of treatment or to the maximum weight) for a maximum of two consecutive days, - Signs of pain, distress or distress: pain posture, facial masking, unusual behavior or screaming, - Poor physical condition, emaciation, listlessness, dehydration, - Bladder outlet obstruction or diarrhea for more than 48 hours, - Chronic lack of spontaneous response to external stimuli, - Shortness of breath, - Anemia, significant bleeding, - bloody or mucopurulent discharge from any orifice, - Neurological signs: circling, twitching, hind limb paralysis, - The body temperature continues to drop, - Abdominal distension.

[0120] Anesthesia and analgesia Isoflurane gas anesthesia was used for test article inoculation and jugular vein blood sampling (if applicable). Nonpharmacological care was provided for all painful procedures. In addition, pharmacological care (topical treatments) that did not interfere with the study could be provided at the advice of the attending veterinarian.

[0121] Euthanasia Animals were euthanized under deep anesthesia using a mixture of Zoltek (30 mg / kg – 0.6 mL / kg) and Xylazine (10 mg / kg – 0.5 mL / kg) injected via the IP route. Gentle cervical dislocation was performed prior to tissue collection, followed by thoracotomy and maximal peripheral blood sampling. If physical methods of euthanasia (cervical dislocation) were necessary, it was performed by highly skilled and trained technicians.

[0122] Statistical analysis Statistical analysis was performed using Prism software (GraphPad Inc., version 8, San Diego, USA). One-way ANOVA test followed by Dunnett's post hoc test For in vivo experiments, quantitative data were compared between animal groups using the Mann-Whitney test. Data represent mean ± SEM. Statistical results were calculated based on one-way ANOVA test. *p<0.05, **p<0.01, ***p<0.001.

[0123] result To complete the in vitro studies on the antiviral effects of QVDM-OPh against SARS-CoV-2, the inventors implemented in vivo assays in the COVID19 Golden Syrian hamster model to demonstrate the efficacy of the QVDM-OPh peptide in inhibiting viral replication in the lungs and compared it with QVE-OPh.

[0124] Compared with the infected and untreated group, the clinical scores and body weight changes of the infected and QVDM-OPh treated group and the infected and QVE-OPh treated group showed promising results compared with day 0 ( Fig.10 A). Although the assay was stopped at dpi 2 and the animals were euthanized at this time point, the results are very encouraging, showing a significant reduction in viral load and viral replication in the lungs of infected and treated animals compared to untreated groups ( Fig.10 B and Fig.10 C). In addition, the reduction in viral load and viral replication was more significant in animals treated with QVDM-OPh (70% reduction in viral replication) compared with animals treated with QVE-QVE-OPh (52% reduction in viral replication).

[0125] All these in vitro and in vivo results confirmed the antiviral effect of QVDM-OPh against SARS-CoV-2 replication.

Claims

1. A method for preventing and / or treating a viral infection caused by SARS-CoV-2 in a patient in need thereof, wherein the method comprises the following steps: The patient in need thereof is administered a compound having the formula (I): or a pharmaceutically acceptable salt or solvate thereof.

2. A method for preventing and / or treating a viral infection caused by SARS-CoV-2 in a patient in need thereof, wherein the method comprises the step of administering to the patient in need thereof a pharmaceutical composition comprising as an active ingredient a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof.

3. The method of claim 2, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable vehicle.

4. The method of claim 2 or 3, wherein the pharmaceutical composition further comprises at least one additional therapeutic agent.

5. A method for preventing and / or treating a viral infection caused by SARS-CoV-2 in a patient in need thereof, wherein the method comprises the step of administering to the patient in need thereof a kit of parts comprising or consisting of: a) a compound of formula (I) as defined in claim 1 or a salt or solvate thereof or a pharmaceutical composition as defined in any one of claims 2 to 4, and b) at least one additional therapeutic agent or a pharmaceutical composition comprising at least one additional therapeutic agent.

6. The method of claim 4 or 5, wherein the at least one additional therapeutic agent is selected from the group consisting of an antiviral agent, an anti-inflammatory agent, an analgesic agent, a muscle relaxant, an anesthetic agent, a diuretic agent, and an antibiotic agent.

7. The method of claim 5 or 6, wherein the at least one additional therapeutic agent is N-(2(quinolyl)-valyl-glutamyl-(2,6-difluorophenoxy)methyl ketone or a pharmaceutically acceptable salt or solvate thereof.

8. The method of claim 6, wherein the antiviral agent is a viral RNA-dependent RNA polymerase modulator or a fusion inhibitor.

9. The method of claim 6, wherein the anti-inflammatory agent is a monoclonal antibody.

10. The method according to any one of claims 1 to 9, wherein the method is implemented to prevent, inhibit and / or reduce viral replication and / or viral protein synthesis in a subject infected with SARS-CoV-2.

11. The method of any one of claims 1 to 9, wherein the method is implemented to prevent complications of COVID-19, such as COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), acute respiratory failure, and liver or heart damage.

Citation Information

Patent Citations

  • Compounds for preventing or treating a viral infection

    WO2009092897A1

  • Compound for preventing or treating a viral infection

    WO2021228846A1